PDCD1 and neoplasm: Since PD-1 is a negative regulatory receptor expressed by immune cells and stimulated by PD-L1, which is usually expressed by tumour cells, anti-PD-1 nanoantibodies can avoid the inhibiting interaction, thus increasing the immune cell response [92].